CureVacCVAC
About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Employees: 1,088
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
12% more call options, than puts
Call options by funds: $322K | Put options by funds: $288K
1.46% less ownership
Funds ownership: 4.97% [Q3] → 3.5% (-1.46%) [Q4]
6% less funds holding
Funds holding: 80 [Q3] → 75 (-5) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 24
19% less capital invested
Capital invested by funds: $32.8M [Q3] → $26.6M (-$6.19M) [Q4]
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
JMP Securities Roy Buchanan 13% 1-year accuracy 3 / 24 met price target | 402%upside $16 | Market Outperform Reiterated | 14 Feb 2025 |
Financial journalist opinion
Based on 8 articles about CVAC published over the past 30 days









